Mandate Vinge advises CELLINK in connection with listing on Nasdaq First North

October 07, 2016

Vinge has advised CELLINK AB (publ) in connection with its listing on Nasdaq First North.

The information memorandum was published on 7 October 2016 and the estimated first day of trading is 3 November 2016. The subscription price in the offer is SEK 26 per share, which corresponds to a pre-money value for CELLINK of approximately MSEK 156. No shares or other securities are being sold by existing shareholders in connection with the offer.

CELLINK develops and sells bioink and bioprinters. Bioink can be combined with conductive cells in order to print functional living tissue and, if future research is successful, complete human organs. CELLINK was founded in 2016 and has won several awards, both scientific and business related, for successful entrepreneurship.

 Vinge’s team consisted of responsible partner Anders Strid together with Frida Bäckegren (capital markets), Jonas Lindblad (employment), Joel Zetterström and Natalie Bäck (IT), Karin Wisenius (competition), Victor Ericsson (tax) and corporate assistant Camilla Andersson.    

Clarification of the interpretation of ”nearest suitable railway station”

Road transport performed by Samskip Sia in Sweden has been confirmed to be within the framework of a permitted combined transport through a decision of the Administrative court of Falun in Sweden. The central question in the case was how to interpret the term “nearest suitable railway station”
June 30, 2020

DAC 6 – EU Directive concerning reportable cross‑border tax arrangements

DAC 6 is a EU Directive which entails that advisers are subject to a duty to notify the relevant tax authorities concerning their client’s cross‑border arrangements. The purpose of the information disclosure obligation is to combat tax evasion, tax fraud and tax avoidance.
June 04, 2020

The importance of continuous focus on compliance procedures in disrupting times

A large number of corporations will most certainly be severely impacted by the effects of the Covid-19 pandemic. The new challenges will impact companies’ compliance risks, which are likely to be different and, to a certain extent, increased. It is crucial that - also in disrupting times - internal compliance procedures are maintained and that new risks are identified and mitigated.
May 28, 2020